Tribendimidine
Appearance
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C28H32N6 |
Molar mass | 452.606 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Tribendimidine is a broad-spectrum anthelmintic agent developed in China, at the National Institute of Parasitic Diseases in Shanghai. It is a derivative of amidantel.[1]
In clinical trials, it was highly effective in treating ankylostomiasis, ascariasis and enterobiasis.[2] It is also effective against clonorchiasis.[3] However, animal studies suggest it is ineffective in treating Schistosoma mansoni or Fasciola hepatica disease.[1] The drug has also performed well in trials against opisthorchiasis, curing about 70% of cases.[4]
Tribendimidine is manufactured by Shandong Xinhua Pharmaceutical Company Limited in Zibo, Shandong, China. It was approved by the China Food and Drug Administration in 2007.[citation needed]
References
[edit]- ^ a b Keiser J, Shu-Hua X, Chollet J, Tanner M, Utzinger J (March 2007). "Evaluation of the in vivo activity of tribendimidine against Schistosoma mansoni, Fasciola hepatica, Clonorchis sinensis, and Opisthorchis viverrini". Antimicrobial Agents and Chemotherapy. 51 (3): 1096–1098. doi:10.1128/AAC.01366-06. PMC 1803157. PMID 17194822. Free full text.
- ^ Xiao SH, Hui-Ming W, Tanner M, Utzinger J, Chong W (April 2005). "Tribendimidine: a promising, safe and broad-spectrum anthelmintic agent from China". Acta Tropica. 94 (1): 1–14. doi:10.1016/j.actatropica.2005.01.013. PMID 15777691.
- ^ Zhang H, Liu C, Zheng Q (December 2019). "Development and application of anthelminthic drugs in China". Acta Tropica. 200: 105181. doi:10.1016/j.actatropica.2019.105181. PMID 31542370.
- ^ Kelland K (2010-11-24). "New drug shows promise against Asian liver fluke". Reuters.